Treatment of Hyperlactatemia in Acute Circulatory Failure Based on Analysis of CO2: a Prospective Randomized Superiority Study (The LACTEL Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-02

Study Completion Date

2023-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The management of a patient with shock is based on improving tissue oxygenation through hemodynamic optimization. Lactate is a marker of tissue hypoperfusion commonly used in the ICU. In principle, hyperlactatemia can be caused by either increased tissue production (tissue hypoperfusion: type A), decreased lactate uptake (type B), or a combination of both mechanisms. It is important to correctly determine the cause(s) of hyperlactatemia, as this determines the treatment (expanders, inotrope, vasopressor, blood derivative transfusion), and the patient's morbidity and mortality. A classic example of this concept is volume expanders, which are frequently used to correct hyperlactatemia secondary to tissue hypoperfusion, but are associated with mortality if used excessively (fluid overload). In clinical practice, it is difficult to differentiate the exact causes of hyperlactatemia (type A and type B). From work carried out over the last 20 years in septic shock and then in other states of shock and in the operating theatre, it has been shown that the arteriovenous CO2 gradient (pCO2gap) measured from arterial and venous blood gases is a marker of tissue hypoperfusion with better predictive ability than the usual markers (clinical examination, SVO2....). Furthermore, when we relate pCO2gap to the arteriovenous O2 difference (pCO2gap /C(a-v)O2), this ratio allows us to distinguish with greater accuracy between states of acute circulatory failure associated with anaerobiosis (tissue hypoperfusion, type A) and those related to the underlying disease.

Also, several studies have demonstrated a strong ability of the pCO2gap and the pCO2gap/CavO2 ratio to predict the severity of shock, mortality of the shock patient, hyperlactatemia, and correction of hyperlactatemia with hemodynamic treatment. As a result, many authors have proposed algorithms for the management of shock patients based on the measurement of these CO2-derived indexes.

The hypothesis of this study is that the use of an algorithm based on CO2gap and the CO2gap/CavO2 ratio is superior in terms of correction of hyperlactatemia to usual practice based on clinical and macro-hemodynamics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Peripheral Perfusion Versus Lactate Targeted Fluid Resuscitation in Septic Shock

NCT03762005

Septic Shock Hyperlactatemia Peripheral Perfusion

UNKNOWN NA

Lactate Clearance Goal-directed Therapy in Sepsis

NCT03256461

Sepsis

UNKNOWN NA

Prognostic Value of Lactates in ICU

NCT04792736

Mortality

COMPLETED

Lactate Metabolism in the Hypoperfused Critically Ill

NCT05582824

Lactate Metabolism Hypoperfusion +2 more

UNKNOWN

Continuous Central Venous Lactate Monitoring by Intravascular Microdialysis : a Comparison to Sequential Arterial Lactate Measurement During Shock.

NCT03464747

Shock

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hyperlactatemia Actue Circulatory Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard practice

Group Type ACTIVE_COMPARATOR

collection of biological data

Intervention Type BIOLOGICAL

collection of biological data

collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data

Intervention Type OTHER

These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.

Standard treatment

Intervention Type PROCEDURE

usual management based on the use of drugs according to international recommendations

algorithm

Group Type EXPERIMENTAL

collection of biological data

Intervention Type BIOLOGICAL

collection of biological data

collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data

Intervention Type OTHER

These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.

stratified treatment according to algorithm

Intervention Type PROCEDURE

management based on arteriovenous CO2 gradient Stratification of drug use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

collection of biological data

Intervention Type BIOLOGICAL

collection of demographic, ventilatory, cardiac echocardiography, arterial and venous gas data

These data are usually measured continuously (monitoring of the resuscitation patient) and recorded on recorded on the resuscitation software.

Intervention Type OTHER

Standard treatment

usual management based on the use of drugs according to international recommendations

Intervention Type PROCEDURE

stratified treatment according to algorithm

management based on arteriovenous CO2 gradient Stratification of drug use

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Oral, free and informed consent obtained from a trusted person (health care proxy) or a close relative or consent in an emergency situation
* Adult patient managed in intensive care for whom the physician has decided on hemodynamic management because of signs of acute circulatory failure (systolic blood pressure \< 90 mmHg, mean arterial pressure \< 65 mmHg, or the need for infusion of vasopressors, skin mottling, diuresis \< 0.5 mL/kg/h for a duration ≥ 2 hours, skin recoloring time \> 3 sec
* Arterial lactate level ≥ 3 mmol L-1

Exclusion Criteria

* Person not affiliated to national health insurance
* Person subject to a measure of legal protection (curatorship, guardianship)
* Person subject to limited judicial protection
* Pregnancy or breastfeeding

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No